Aspirin reduces the incidence of metastatic Braf mutant colorectal cancer in a preclinical trial

被引：0
|
作者：
Kane, A. [1 ,2 ,3 ]
Mckeone, D. [1 ]
Liu, C. [1 ,2 ]
Borowsky, J. [1 ,2 ,3 ]
Leggett, B. [1 ,2 ,4 ]
Whitehall, V. [1 ,2 ,3 ]
机构：
[1] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia
[2] Univ Queensland, Brisbane, Qld, Australia
[3] Pathol Queensland, Brisbane, Qld, Australia
[4] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2019年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
213
引用
收藏
页码：33 / 33
页数：1
相关论文
共 50 条
  • [31] Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial
    Kopetz, Scott
    Murphy, Danielle A.
    Pu, Jie
    Ciardiello, Fortunato
    Desai, Jayesh
    Van Cutsem, Eric
    Wasan, Harpreet Singh
    Yoshino, Takayuki
    Saffari, Hedieh
    Zhang, Xiaosong
    Hamilton, Phineas
    Xie, Tao
    Yaeger, Rona
    Tabernero, Josep
    NATURE MEDICINE, 2024, 30 (11) : 3261 - 3271
  • [32] Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406).
    Kopetz, Scott
    McDonough, Shannon L.
    Lenz, Heinz -Josef
    Magliocco, Anthony Martin
    Atreya, Chloe Evelyn
    Diaz, Luis A.
    Allegra, Carmen Joseph
    Raghav, Kanwal Pratap Singh
    Morris, Van Karlyle
    Wang, Stephen E.
    Lieu, Christopher Hanyoung
    Guthrie, Katherine A.
    Hochster, Howard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)
    Kopetz, Scott
    Guthrie, Katherine A.
    Morris, Van K.
    Lenz, Heinz-Josef
    Magliocco, Anthony M.
    Maru, Dipen
    Yan, Yibing
    Lanman, Richard
    Manyam, Ganiraju
    Hong, David S.
    Sorokin, Alexey
    Atreya, Chloe E.
    Diaz, Luis A.
    Allegra, Carmen
    Raghav, Kanwal P.
    Wang, Stephen E.
    Lieu, Christopher H.
    McDonough, Shannon L.
    Philip, Philip A.
    Hochster, Howard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (04) : 285 - +
  • [34] BRAF Mutation in Metastatic Colorectal Cancer.
    Tol, Jolien
    Nagtegaal, Iris D.
    Punt, Cornelis J. A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (01): : 98 - 99
  • [35] Clinicopathologic features and impact of metastasectomy in patients with BRAF-mutant metastatic colorectal cancer.
    Zhang, Jianwei
    Shen, Cailu
    Li, Jianxia
    Wu, Zehua
    Hu, Huabin
    Cai, Yue
    Xie, Xiaoyu
    Ling, Jiayu
    Deng, Yanhong
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] A case series on eruptive melanocytic naevi in the setting of encorafenib for metastatic BRAF mutant colorectal cancer
    Kok, Yonatan
    McDonald, Priska
    Tizi, Stephanie
    Goh, Michelle
    McCormack, Christopher
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 95 - 95
  • [37] Activity of EGFR antibody in non-V600 BRAF mutant metastatic colorectal cancer
    Wang, Y.
    Jones, J. C.
    Kipp, B. R.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2019, 30 (01) : 147 - 149
  • [38] RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer-Letter
    Sorscher, Steven
    CLINICAL CANCER RESEARCH, 2015, 21 (09) : 2187 - 2187
  • [39] FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
    Loupakis, F.
    Cremolini, C.
    Salvatore, L.
    Masi, G.
    Sensi, E.
    Schirripa, M.
    Michelucci, A.
    Pfanner, E.
    Brunetti, I.
    Lupi, C.
    Antoniotti, C.
    Bergamo, F.
    Lonardi, S.
    Zagonel, V.
    Simi, P.
    Fontanini, G.
    Falcone, A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) : 57 - 63
  • [40] RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer-Response
    Yaeger, Rona
    Saltz, Leonard B.
    CLINICAL CANCER RESEARCH, 2015, 21 (09) : 2188 - 2188
12345